Please login to the form below

Not currently logged in
Email:
Password:

Sanofi appoints Diane Souza and Thomas Südhof

They join the board as independent directors

Sanofi has appointed Diane Souza and Thomas Südhof to its board of directors as independent directors, effective 4 May.

Souza brings over 25 years of managed care and health benefits expertise as well as financial management experience to the board. She most recently served as chief executive officer of UnitedHealthcare Speciality Benefits, a voluntary health insurance business.

Prior to this, Souza held the role of chief financial officer at Aetna, overseeing its guaranteed products business, and has also held senior leadership positions at Deloitte and PriceWaterhouseCooper.

Meanwhile, Südhof currently serves as the Avram Goldstein professor and professor of molecular and cellular physiology, psychiatry and neurology at Stanford University's school of medicine.

Before joining Stanford, he spent 25 years at the University of Texas as chairman of the department of neuroscience researching neuro-degenerative and neuro-psychiatric diseases. Südhof was a member of team who won the Nobel Prize in physiology or medicine in 2013.

Serge Weinberg, chairman of Sanofi's board, said: “Both Diane Souza and Thomas Südhof are noted health experts and their great skills make them an outstanding addition to our board.

“We look forward to their contribution to Sanofi's strategy as we continue to innovate and introduce new medicines and vaccines that can help improve health outcomes.”

22nd March 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics